{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:37Z","timestamp":1792788277292,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangsu Provincial Research Hospital","award":["YJXYY202204-YSC01, YJXYY202204-YSB01"],"award-info":[{"award-number":["YJXYY202204-YSC01, YJXYY202204-YSB01"]}]},{"name":"Nantong Basic Research Plan Project","award":["MS2023067"],"award-info":[{"award-number":["MS2023067"]}]},{"name":"National Natural Science Foundation of China","award":["No. 82273422"],"award-info":[{"award-number":["No. 82273422"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-026-01793-9","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:15:41Z","timestamp":1783404941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CLDN18.2 expression identifies a gastric-type phenotype and a potential therapeutic target in pulmonary invasive mucinous adenocarcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Tingting","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daishan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"1","key":"1793_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/his.15064","volume":"84","author":"WC Chang","year":"2024","unstructured":"Chang WC, Zhang YZ, Nicholson AG. Pulmonary invasive mucinous adenocarcinoma. Histopathology. 2024;84(1):18\u201331. https:\/\/doi.org\/10.1111\/his.15064.","journal-title":"Histopathology"},{"issue":"6","key":"1793_CR2","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.21037\/tlcr-24-526","volume":"13","author":"X Pan","year":"2024","unstructured":"Pan X, Fang R, Zhang B, Chen Z, Zhang S, Le H, et al. Pathological and imaging features of pulmonary invasive mucinous adenocarcinoma-a retrospective cohort study. Transl Lung Cancer Res. 2024;13(6):1376\u201382. https:\/\/doi.org\/10.21037\/tlcr-24-526.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"1793_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12957-024-03326-4","volume":"22","author":"T Zhao","year":"2024","unstructured":"Zhao T, Yi J, Luo D, Liu J, Fan X, Wu Q, et al. Prognostic factors for invasive mucinous adenocarcinoma of the lung: systematic review and meta-analysis. World J Surg Oncol. 2024;22(1):41. https:\/\/doi.org\/10.1186\/s12957-024-03326-4.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"1793_CR4","doi-asserted-by":"publisher","first-page":"108053","DOI":"10.1016\/j.ejso.2024.108053","volume":"50","author":"J Lee","year":"2024","unstructured":"Lee J, Cho S, Chung JH, Yoon SH, Shih BC, Jung W, et al. Prognosis of spread through air spaces in invasive mucinous lung adenocarcinoma after curative surgery. Eur J Surg Oncol. 2024;50(4):108053. https:\/\/doi.org\/10.1016\/j.ejso.2024.108053.","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"1793_CR5","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1111\/1759-7714.13632","volume":"11","author":"MA Lee","year":"2020","unstructured":"Lee MA, Kang J, Lee HY, Kim W, Shon I, Hwang NY, et al. Spread through air spaces (STAS) in invasive mucinous adenocarcinoma of the lung: Incidence, prognostic impact, and prediction based on clinicoradiologic factors. Thorac Cancer. 2020;11(11):3145\u201354. https:\/\/doi.org\/10.1111\/1759-7714.13632.","journal-title":"Thorac Cancer"},{"key":"1793_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.06.004","author":"K Masago","year":"2025","unstructured":"Masago K, Kuroda H, Seto K, Sasaki E, Fujita Y, Horio Y, et al. Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung. Clin Lung Cancer. 2025. https:\/\/doi.org\/10.1016\/j.cllc.2025.06.004.","journal-title":"Clin Lung Cancer"},{"key":"1793_CR7","doi-asserted-by":"publisher","first-page":"683432","DOI":"10.3389\/fonc.2021.683432","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Li N, Wang D, Chen W, Fan Y. Clinical Relevance of PD-L1 Expression and CD8\u2009+\u2009T Cells\u2019 Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma. Front Oncol. 2021;11:683432. https:\/\/doi.org\/10.3389\/fonc.2021.683432.","journal-title":"Front Oncol"},{"issue":"52","key":"1793_CR8","doi-asserted-by":"publisher","first-page":"e41161","DOI":"10.1097\/md.0000000000041161","volume":"103","author":"M Qian","year":"2024","unstructured":"Qian M, Lyu R, Xiao L, Shi B, Liu N, Yuan Y, et al. Pulmonary mucinous adenocarcinoma: A case report and literature review. Med (Baltim). 2024;103(52):e41161. https:\/\/doi.org\/10.1097\/md.0000000000041161.","journal-title":"Med (Baltim)"},{"issue":"3","key":"1793_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.annonc.2024.11.014","volume":"36","author":"A Di Federico","year":"2025","unstructured":"Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, et al. Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS(G12C) inhibitors. Ann Oncol. 2025;36(3):297\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.014.","journal-title":"Ann Oncol"},{"issue":"7","key":"1793_CR10","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1016\/j.cllc.2024.05.004","volume":"25","author":"T Demir","year":"2024","unstructured":"Demir T, Araz M, Moloney C, Hendem E, Ko\u00e7ak MZ, Erman M, et al. Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma. Clin Lung Cancer. 2024;25(7):e316\u201322. https:\/\/doi.org\/10.1016\/j.cllc.2024.05.004.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"1793_CR11","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.21037\/tcr-19-1876","volume":"9","author":"JY Hong","year":"2020","unstructured":"Hong JY, An JY, Lee J, Park SH, Park JO, Park YS, et al. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res. 2020;9(5):3367\u201374. https:\/\/doi.org\/10.21037\/tcr-19-1876.","journal-title":"Transl Cancer Res"},{"issue":"10389","key":"1793_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/s0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(23)00620-7.","journal-title":"Lancet"},{"issue":"8","key":"1793_CR13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"8","key":"1793_CR14","doi-asserted-by":"publisher","first-page":"103663","DOI":"10.1016\/j.esmoop.2024.103663","volume":"9","author":"F Lordick","year":"2024","unstructured":"Lordick F, Van Cutsem E, Shitara K, Xu RH, Ajani JA, Shah MA, et al. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024;9(8):103663. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103663.","journal-title":"ESMO Open"},{"issue":"14","key":"1793_CR15","doi-asserted-by":"publisher","first-page":"12923","DOI":"10.1007\/s00432-023-05150-x","volume":"149","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gao Y, Zhang Z, Zhang Z, Wang A, Zhao K, et al. Claudin18.2 expression in pulmonary mucinous adenocarcinoma. J Cancer Res Clin Oncol. 2023;149(14):12923\u20139. https:\/\/doi.org\/10.1007\/s00432-023-05150-x.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1793_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-209268","author":"P Yan","year":"2024","unstructured":"Yan P, Dong Y, Zhang F, Zhen T, Liang J, Shi H, et al. Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts. J Clin Pathol. 2024. https:\/\/doi.org\/10.1136\/jcp-2023-209268.","journal-title":"J Clin Pathol"},{"issue":"3","key":"1793_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2022","unstructured":"Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17(3):362\u201387. https:\/\/doi.org\/10.1016\/j.jtho.2021.11.003.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"1793_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.21037\/tlcr.2020.01.06","volume":"9","author":"M Mino-Kenudson","year":"2020","unstructured":"Mino-Kenudson M. Significance of tumor spread through air spaces (STAS) in lung cancer from the pathologist perspective. Transl Lung Cancer Res. 2020;9(3):847\u201359. https:\/\/doi.org\/10.21037\/tlcr.2020.01.06.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"1793_CR19","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1111\/1759-7714.13918","volume":"12","author":"T Ikeda","year":"2021","unstructured":"Ikeda T, Kadota K, Go T, Haba R, Yokomise H. Current status and perspectives of spread through air spaces in lung cancer. Thorac Cancer. 2021;12(11):1639\u201346. https:\/\/doi.org\/10.1111\/1759-7714.13918.","journal-title":"Thorac Cancer"},{"issue":"9","key":"1793_CR20","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ijc.28857","volume":"135","author":"P Micke","year":"2014","unstructured":"Micke P, Mattsson JS, Edlund K, Lohr M, Jirstr\u00f6m K, Berglund A, et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer. 2014;135(9):2206\u201314. https:\/\/doi.org\/10.1002\/ijc.28857.","journal-title":"Int J Cancer"},{"issue":"6","key":"1793_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/pas.0000000000002222","volume":"48","author":"H Rokutan","year":"2024","unstructured":"Rokutan H, Arai Y, Kunita A, Yamasaki S, Nakamura H, Hama N, et al. Genomic and Pathologic Profiling of Very Well-Differentiated Gastric Adenocarcinoma of Intestinal Type: A Study With Emphasis on Diffuse-Type Transformation. Am J Surg Pathol. 2024;48(6):652\u201361. https:\/\/doi.org\/10.1097\/pas.0000000000002222.","journal-title":"Am J Surg Pathol"},{"key":"1793_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.lungcan.2017.05.007","volume":"109","author":"M Duruisseaux","year":"2017","unstructured":"Duruisseaux M, Antoine M, Rabbe N, Rodenas A, Mc Leer-Florin A, Lacave R, et al. Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers. Lung Cancer. 2017;109:92\u2013100. https:\/\/doi.org\/10.1016\/j.lungcan.2017.05.007.","journal-title":"Lung Cancer"},{"issue":"4","key":"1793_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41379-020-00690-w","volume":"34","author":"S Kishikawa","year":"2021","unstructured":"Kishikawa S, Hayashi T, Saito T, Takamochi K, Kohsaka S, Sano K, et al. Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma. Mod Pathol. 2021;34(4):786\u201397. https:\/\/doi.org\/10.1038\/s41379-020-00690-w.","journal-title":"Mod Pathol"},{"issue":"1","key":"1793_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/his.15432","volume":"87","author":"M Plass","year":"2025","unstructured":"Plass M, Olteanu GE, Dacic S, Kern I, Zacharias M, Popper H, et al. Comparative performance of PD-L1 scoring by pathologists and AI algorithms. Histopathology. 2025;87(1):90\u2013100. https:\/\/doi.org\/10.1111\/his.15432.","journal-title":"Histopathology"},{"issue":"1","key":"1793_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5146\/tjpath.2022.01593","volume":"39","author":"M Buyuk","year":"2023","unstructured":"Buyuk M, Ozluk Y, Bakkaloglu DV, Ozkan B, Firat P, Yilmazbayhan D. Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). Turk Patoloji Derg. 2023;39(1):64\u201374. https:\/\/doi.org\/10.5146\/tjpath.2022.01593.","journal-title":"Turk Patoloji Derg"},{"issue":"7511","key":"1793_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Comprehensive molecular profiling of lung adenocarcinoma","year":"2014","unstructured":"Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350. https:\/\/doi.org\/10.1038\/nature13385.","journal-title":"Nature"},{"issue":"1","key":"1793_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jtho.2018.09.005","volume":"14","author":"T Eguchi","year":"2019","unstructured":"Eguchi T, Kameda K, Lu S, Bott MJ, Tan KS, Montecalvo J, et al. Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis. J Thorac Oncol. 2019;14(1):87\u201398. https:\/\/doi.org\/10.1016\/j.jtho.2018.09.005.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"1793_CR28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1097\/pas.0000000000001285","volume":"43","author":"K Kadota","year":"2019","unstructured":"Kadota K, Kushida Y, Kagawa S, Ishikawa R, Ibuki E, Inoue K, et al. Limited Resection Is Associated With a Higher Risk of Locoregional Recurrence than Lobectomy in Stage I Lung Adenocarcinoma With Tumor Spread Through Air Spaces. Am J Surg Pathol. 2019;43(8):1033\u201341. https:\/\/doi.org\/10.1097\/pas.0000000000001285.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1793_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.athoracsur.2018.02.076","volume":"106","author":"S Shiono","year":"2018","unstructured":"Shiono S, Endo M, Suzuki K, Yarimizu K, Hayasaka K, Yanagawa N. Spread Through Air Spaces Is a Prognostic Factor in Sublobar Resection of Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018;106(2):354\u201360. https:\/\/doi.org\/10.1016\/j.athoracsur.2018.02.076.","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"1793_CR30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/icvts\/ivab289","volume":"34","author":"S Mantovani","year":"2022","unstructured":"Mantovani S, Pernazza A, Bassi M, Amore D, Vannucci J, Poggi C, et al. Prognostic impact of spread through air spaces in lung adenocarcinoma. Interact Cardiovasc Thorac Surg. 2022;34(6):1011\u20135. https:\/\/doi.org\/10.1093\/icvts\/ivab289.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"1793_CR31","doi-asserted-by":"publisher","unstructured":"Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, et al. Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. Cancers (Basel). 2018;10(12). https:\/\/doi.org\/10.3390\/cancers10120478.","DOI":"10.3390\/cancers10120478"},{"issue":"14","key":"1793_CR32","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/1078-0432.Ccr-21-0423","volume":"27","author":"JC Chang","year":"2021","unstructured":"Chang JC, Offin M, Falcon C, Brown D, Houck-Loomis BR, Meng F, et al. Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clin Cancer Res. 2021;27(14):4066\u201376. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0423.","journal-title":"Clin Cancer Res"},{"key":"1793_CR33","doi-asserted-by":"publisher","first-page":"104401","DOI":"10.1016\/j.critrevonc.2024.104401","volume":"200","author":"A La Salvia","year":"2024","unstructured":"La Salvia A, Meyer ML, Hirsch FR, Kerr KM, Landi L, Tsao MS, et al. Rediscovering immunohistochemistry in lung cancer. Crit Rev Oncol Hematol. 2024;200:104401. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104401.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1793_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"issue":"5","key":"1793_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21(5):354\u201369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-026-01793-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:11:23Z","timestamp":1790723483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13000-026-01793-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1186\/s13000-026-01793-9","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of the Affiliated Hospital of Nantong University (Approval No. 2022-L078) and conducted in accordance with the Declaration of Helsinki (as revised in 2013). Owing to the retrospective design and anonymised data, the requirement for written informed consent was waived.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is original, has not been published elsewhere, and is not under consideration by any other publication. All authors have read and approved the final version of the manuscript and agree with its submission to Diagnostic Pathology.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"68"}}